KDR and neoplasm: Taken together, the data argue that the injection of VEGFR2 targeting cRGD-siRNA conjugate molecules results in the effective and specific reduction of tumor growth, likely due to the inhibition of tissue angiogenesis and apoptosis of cancer cells.